Historique
Article de Périodique
Pharmaceutical regulation failures and changes: Lessons learned from OxyContin abuse and diversion (2013)
Auteur(s) :
GRIFFIN III, O. H. ;
SPILLANE, J. F.
Année
2013
Page(s) :
164-175
Langue(s) :
Anglais
Domaine :
Autres substances / Other substances
Discipline :
SAN (Santé publique / Public health)
Thésaurus mots-clés
REGULATION
;
OPIOIDES
;
ABUS
;
MEDICAMENTS
;
MESUSAGE
;
REGLEMENTATION
;
SURVEILLANCE EPIDEMIOLOGIQUE
;
INDUSTRIE DU MEDICAMENT
Thésaurus géographique
ETATS-UNIS
Résumé :
OxyContin, a controlled-release opioid developed and produced by Purdue Pharma, was given Food and Drug Administration (FDA) approval in December 1995. By 1999, to the apparent surprise of Purdue Pharma, the Drug Enforcement Administration (DEA), and the FDA, extensive reports of OxyContin abuse and diversion began to circulate. The drug abuse assessment liability system in the United States has often been criticized and the experience with OxyContin did nothing but buttress those criticisms. However, as seven investigational hearings conducted by the U.S. Congress would expose, several changes were made to the abuse liability assessment to correct deficiencies in the system which had aggravated OxyContin abuse and diversion - a welcome sign from what many have considered an American tragedy.
Affiliation :
School of Criminal Justice, The University of Southern Mississippi, Hattiesburg, MS, USA
Cote :
Abonnement